{
    "info": {
        "nct_id": "NCT04641247",
        "official_title": "An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib",
        "inclusion_criteria": "* Participant is able to understand the study procedures and agrees to participate in the study by providing written informed consent.\n* Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.\n* Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective.\n* Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.\n* Participants of childbearing potential who are sexually active and their partners must agree to the use of an effective form of contraception throughout their participation during study treatment through 180 days after last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participant has been permanently discontinued from niraparib treatment in the parent study for any reason.\n* Participant currently has unresolved toxicities for which niraparib dosing has been interrupted in the parent study. Participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow niraparib treatment to resume.\n* Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use during niraparib treatment and for 30 days after receiving the final dose of study treatment).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is able to understand the study procedures and agrees to participate in the study by providing written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Participant is able to understand the study procedures",
                    "criterion": "ability to understand study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to participate in the study by providing written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Participant is willing and able to comply with scheduled visits",
                    "criterion": "compliance with scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant is willing and able to comply with ... treatment plans",
                    "criterion": "compliance with treatment plans",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant is willing and able to comply with ... any other study procedures",
                    "criterion": "compliance with other study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "currently benefiting from treatment with niraparib",
                    "criterion": "benefit from niraparib treatment",
                    "requirements": [
                        {
                            "requirement_type": "current benefit",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by the Investigator according to the parent study protocol requirements",
                    "criterion": "assessment by Investigator according to parent study protocol",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "according to parent study protocol"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants of childbearing potential who are sexually active and their partners must agree to the use of an effective form of contraception throughout their participation during study treatment through 180 days after last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Participants of childbearing potential who are sexually active and their partners must agree to the use of an effective form of contraception throughout their participation during study treatment through 180 days after last dose of study drug.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception type",
                            "expected_value": "effective form"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "throughout their participation during study treatment through 180 days after last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants of childbearing potential who are sexually active",
                    "criterion": "childbearing potential and sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective.",
            "criterions": [
                {
                    "exact_snippets": "Participant is currently receiving treatment with niraparib (as monotherapy or in combination)",
                    "criterion": "current treatment with niraparib",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in a GlaxoSmithKline/TESARO-sponsored study",
                    "criterion": "participation in GlaxoSmithKline/TESARO-sponsored study",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that has fulfilled the requirements for the primary objective",
                    "criterion": "fulfillment of primary objective requirements in study",
                    "requirements": [
                        {
                            "requirement_type": "primary objective fulfilled",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participant has been permanently discontinued from niraparib treatment in the parent study for any reason.",
            "criterions": [
                {
                    "exact_snippets": "Participant has been permanently discontinued from niraparib treatment in the parent study",
                    "criterion": "niraparib treatment status in the parent study",
                    "requirements": [
                        {
                            "requirement_type": "permanent discontinuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant currently has unresolved toxicities for which niraparib dosing has been interrupted in the parent study. Participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow niraparib treatment to resume.",
            "criterions": [
                {
                    "exact_snippets": "Participant currently has unresolved toxicities for which niraparib dosing has been interrupted",
                    "criterion": "unresolved toxicities related to niraparib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "toxicities have resolved to allow niraparib treatment to resume",
                    "criterion": "resolution of toxicities related to niraparib",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use during niraparib treatment and for 30 days after receiving the final dose of study treatment).",
            "criterions": [
                {
                    "exact_snippets": "Participant is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug",
                    "criterion": "expectation to conceive children",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 180,
                                        "unit": "days after last dose"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant is breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to breastfeed within 30 days of receiving the final dose of study drug",
                    "criterion": "expectation to breastfeed",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days after final dose"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}